---
type: connection
sweep_date: 2026-05-15
sweep_sha: 8653de9
section_index: 2
global_index: 2
pass3_verdict: Confirmed, prioritize
overlap_tag: EXTENSION
---

# The genotype-informed supplement quantification workflow (`self-experiment-protocol.md` §12) composes three previously disconnected platform threads into a closed-loop n=1 pharmacogenomics pipeline.

2. **The genotype-informed supplement quantification workflow (`self-experiment-protocol.md` §12) composes three previously disconnected platform threads into a closed-loop n=1 pharmacogenomics pipeline.** *Supported.* `[CHAIN-DEPTH: 3+]` `[PHASE-A-MATCH: no]`
   - *Documents Connected:* [`self-experiment-protocol.md`](./self-experiment-protocol.md), [`personal-genome-protocol.md`](./personal-genome-protocol.md), [`quantification-ladder.md`](./quantification-ladder.md), [`enzyme-quantification-protocol.md`](./enzyme-quantification-protocol.md), [`medicinal-mushroom-extract-sops.md`](./medicinal-mushroom-extract-sops.md), [`gout-action-guide.md`](./gout-action-guide.md), [`t-axis-adjuvant-urate-mapping-computational.md`](./t-axis-adjuvant-urate-mapping-computational.md)
   - *Page-pair linkage:* `self-experiment-protocol.md` §12 is newly added (2026-05-15) and explicitly names the composition of `personal-genome-protocol.md` + `quantification-ladder.md` + the track-specific assay pages. Prior to this, the three threads (genotype-informed compound selection, home/community-biolab batch QC, and biomarker-tracked self-experimentation) were individually well-developed but not connected into a named workflow. The chain composes: (1) clinical-grade genotyping → variant-informed compound selection (e.g., ABCG2 Q141K → butyrate emphasis; URAT1 gain-of-function → cordycepin > eurycomanone per comp-015 v2), (2) home or community-biolab production of the selected compound, (3) Tier 2 batch QC via the quantification ladder to verify actual delivered dose, (4) calibrated dosing against the verified batch potency, and (5) biomarker tracking per the self-experiment protocol. This converts supplement dose from a fixed assumed input into a verified variable, closing a major source of invisible noise in n=1 pharmacogenomics.
   - *Why It Matters:* The platform's self-experiment and community-fermentation theses both depend on the assumption that "what the user thinks they're taking" matches "what they're actually taking." Without batch QC, silent underdosing (a batch producing 20% of expected titer) is indistinguishable from mechanism failure. The workflow closes that loop. It also makes the platform's genotype-stratified recommendations (e.g., the androgen-elevated path in `gout-action-guide.md`) operationally testable: a Q141K-positive user can genotype → select butyrate-emphasis stack → produce or source the compound → Tier 2 verify potency → track SUA trajectory, with each link in the chain verified rather than assumed. This is the operational backbone that H09 (Community Fermentation Reliability) needs to demonstrate, and it's the user-facing instantiation of the platform's "open-source, democratized, rigorous" thesis.
   - *Suggested Action:* Promote `self-experiment-protocol.md` §12 from a section to a dedicated wiki page (`wiki/genotype-informed-supplement-workflow.md`) that serves as the user-facing entry point for the closed-loop pipeline. Cross-link from `gout-action-guide.md`'s "This year (advanced)" sections, `personal-genome-protocol.md`, and each track-specific assay page. The workflow is specified; what's missing is a single canonical surface that a new user can follow end-to-end.

> **Pass 3 review — Confirmed, prioritize.** `[OVERLAP: EXTENSION]` The workflow is correctly identified as a practical closed loop: `self-experiment-protocol.md` §12 explicitly composes genotype-informed selection, Tier 2 batch QC, calibrated dosing, and biomarker tracking, while `quantification-ladder.md` defines the calibrate-once-at-Tier-3 / track-batches-cheap operating model. Tool check confirms `wiki/genotype-informed-supplement-workflow.md` does not yet exist, so promoting §12 to a standalone page is a real discoverability action rather than a duplicate-file edit.

---

## ✓ Actioned 2026-05-16

Promoted `self-experiment-protocol.md §12` to standalone page `wiki/genotype-informed-supplement-workflow.md` with full content lift + standalone reframing (page-level intro replacing "added 2026-05-15 to §12" framing). Workflow detail: five-step closed-loop pipeline (genotype → selection → produce/source → Tier 2 batch QC → calibrated dose → biomarker tracking) with the Q141K butyrate-emphasis worked example. Added an "H09 dependency" note explicitly stating the workflow shape survives if H09 fails (genotype-informed selection + dose calibration + biomarker tracking still work; the home-production step routes through commercial supplements instead).

- [`wiki/genotype-informed-supplement-workflow.md`](../../wiki/genotype-informed-supplement-workflow.md) — new standalone page (~190 lines)
- [`wiki/self-experiment-protocol.md` §12](../../wiki/self-experiment-protocol.md) — content replaced with 3-line pointer to new page
- [`wiki/personal-genome-protocol.md`](../../wiki/personal-genome-protocol.md) §"See also" — promoted workflow to first / boldface entry; characterized as "canonical user-facing closed-loop pipeline; the promoted version of §12"
- [`wiki/quantification-ladder.md`](../../wiki/quantification-ladder.md) §"See also" — promoted workflow to first / boldface entry; characterized as the workflow that uses this ladder as its steps 3–4
- [`wiki/gout-action-guide.md`](../../wiki/gout-action-guide.md) "This year (advanced)" — new lead bullet pointing at the workflow as the user-facing entry point; existing genotyping + self-experiment bullets framed as prerequisites
- [`index.md`](../../index.md) Core Pathology & Targets — new listing for the workflow

Cluster-closure: closes with Item 21 (Priority Action 2) via the same promotion action. Pointer maintained in each.
